UBS Downgrades Merck (MRK) to Neutral
UBS downgrades Merck (NYSE: MRK) from Buy to Neutral and cuts its price target from $43 to $40.
Merck & Co., Inc. provides various products for human and animal health in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
